1. Home
  2. TRVI vs LILAK Comparison

TRVI vs LILAK Comparison

Compare TRVI & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$13.31

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

SELL

Current Price

$9.86

Market Cap

1.7B

ML Signal

SELL

Company Overview

Basic Information
Metric
TRVI
LILAK
Founded
2011
2017
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
TRVI
LILAK
Price
$13.31
$9.86
Analyst Decision
Strong Buy
Hold
Analyst Count
11
2
Target Price
★ $28.18
$8.20
AVG Volume (30 Days)
1.5M
★ 1.8M
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 31.91
7.55
EPS
★ N/A
N/A
Revenue
N/A
★ $4,442,200,000.00
Revenue This Year
N/A
$0.60
Revenue Next Year
N/A
$3.23
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.82
$4.75
52 Week High
$20.22
$10.42

Technical Indicators

Market Signals
Indicator
TRVI
LILAK
Relative Strength Index (RSI) 46.10 68.05
Support Level $13.00 $7.44
Resistance Level $13.55 N/A
Average True Range (ATR) 0.88 0.48
MACD 0.06 0.16
Stochastic Oscillator 20.92 78.41

Price Performance

Historical Comparison
TRVI
LILAK

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

Share on Social Networks: